A naive bayes classifier for prediction of multidrug resistance reversal activity on the basis of atom typing
1Discovery Chemistry, Hoffmann-La Roche Inc., Nutley, New Jersey 07110, USA. hongmao.sun@roche.com
Abstract:
Multidrug resistance (MDR), the ability of cancer cells to become simultaneously resistant to different drugs, remains an unsolved challenge in cancer chemotherapy. The use of MDR reversal (MDRR) agents is a promising approach to overcome this problem. For the design and development of such agents, it would be desirable to have a reliable model to estimate the MDRR activity of compounds. Presented here is a naive Bayes classifier to categorize MDRR agents into active and inactive classes, which uses a universal, generic molecular-descriptor system.(1) The naive Bayes classifier was built from a 424 compound training set, selected from 609 druglike compounds in the publicly available "Klopman set". The model correctly predicted MDRR activities for 82.2% of 185 compounds in a testing set. The cumulative probabilities were proven useful for prioritizing the compounds for testing. The impact of attribute dependences on the performance of the classifier was examined. As an unsupervised learner with no tuning parameters, a naive Bayes classifier is capable of providing an objective comparison of the effectiveness of different molecular descriptors. The relative performance of the classifiers constructed from either an atom-type-based molecular descriptor or the long-range functional-class fingerprint descriptors FCFP_6 or FCFP_2 was compared. Employing an atom typing descriptor with the naive Bayes classification, it enables the interpretability of the resulting model, which offers extra information for the rational design of MDRR agents.
Insights
This study introduces a naive Bayes classifier to predict multidrug resistance reversal (MDRR) agents. The model accurately identifies active MDRR compounds, aiding in the development of new cancer chemotherapy strategies.
Area of Science:
- Computational chemistry
- Cheminformatics
- Drug discovery
Background:
- Multidrug resistance (MDR) in cancer chemotherapy poses a significant challenge.
- MDR reversal (MDRR) agents offer a promising strategy to overcome drug resistance.
- Developing reliable models to predict MDRR activity is crucial for rational drug design.
Purpose of the Study:
- To develop and validate a naive Bayes classifier for predicting MDRR agent activity.
- To utilize a universal molecular descriptor system for classifying MDRR compounds.
- To facilitate the rational design of novel MDRR agents.
Main Methods:
- A naive Bayes classifier was trained on a dataset of 424 compounds.
- The model was tested on 185 compounds, achieving 82.2% prediction accuracy.
- Comparative analysis of atom-type descriptors versus functional-class fingerprints (FCFP_6, FCFP_2) was performed.
Main Results:
- The naive Bayes classifier demonstrated strong predictive performance for MDRR activity.
- Cumulative probabilities from the model proved useful for prioritizing compounds.
- Atom-type descriptors enabled model interpretability, providing insights for drug design.
Conclusions:
- The developed naive Bayes classifier is an effective tool for categorizing MDRR agents.
- The model aids in the rational design and development of new chemotherapy drugs.
- This approach offers an objective method for comparing molecular descriptors in drug discovery.
More Related Videos
05:06Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Development of Antibiotic Resistance
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Predicting Reaction Outcomes
